Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...

Over the course of two weeks we tested the speaker’s sound for everything from Spotify to audiobooks and live radio (iStock/The Independent) Audio Pro’s C5A speaker sits right in the middle of Audio ...

JENA, Germany, Feb. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today ...

C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the ...

A recent study posted to the bioRxiv* preprint server investigated the role of complement component 5a (C5a) and its receptor (C5a receptor type 1, C5aR1) in the pathophysiology of coronavirus disease ...

The AMD-powered C5a instances offer high performance while consuming 10% less cost compared to its competitors. They come in eight sizes and are generally available starting today. Starting today, ...